Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Estey

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Annals of Hematology|May 6, 2004
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trialR M Stone, J De Angelo, I Galinsky, et al.
Cancer|November 7, 2000
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemiaS Faderl, H M Kantarjian, E Estey, et al.
American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study GroupP Greenberg, J Anderson, T de Witte, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Leukemia|May 24, 2003
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyA-M Tsimberidou, H M Kantarjian, E Estey, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Leukemia|September 15, 2015
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromeN Daver, H Kantarjian, F Ravandi, et al.
Blood|June 15, 1997
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapyS Giralt, E Estey, M Albitar, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Annals of Hematology|May 6, 2004
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trialR M Stone, J De Angelo, I Galinsky, et al.
Cancer|November 7, 2000
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemiaS Faderl, H M Kantarjian, E Estey, et al.
American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study GroupP Greenberg, J Anderson, T de Witte, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Leukemia|May 24, 2003
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyA-M Tsimberidou, H M Kantarjian, E Estey, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Leukemia|September 15, 2015
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromeN Daver, H Kantarjian, F Ravandi, et al.
Blood|June 15, 1997
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapyS Giralt, E Estey, M Albitar, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Pageof 21